Blood cancers such as leukemia and lymphoma are aggressive and have high relapse rates, posing significant challenges for treatment. Chimeric Antigen Receptors (CAR)-T cell therapy, an innovative approach that modifies a patient’s T cells to target cancer cells, has shown promise for relapsed or refractory cases. However, patients undergoing CAR-T therapy often experience severe symptoms and reduced quality of life. Specialized palliative care ( SPC) can address these issues by providing holistic support to improve physical, psychological, and emotional well-being. This study aims to improve the quality of life for patients with relapsed or refractory blood cancers undergoing CAR- T Cell therapy. We will assess the feasibility and effectiveness of SPC into their treatment. SPC focuses on managing symptoms, pain, and stress to improve overall well-being. Our goal is to determine if SPC can enhance patients’ quality of life and reduce symptoms during CAR-T cell therapy. Patients will receive comprehensive care addressing physical, psychological, nursing, and social needs. It is a pilot single-arm single-center prospective observational study with duration of 4 months and study population includes adults aged more than 18 with relapsed / refractory blood cancers eligible for CAR-T therapy. We will assess quality of life and symptom burden at three time points: before CAR-T cell therapy, 1 day before initiating therapy, and 28 days after therapy. This study will provide valuable insights into improving care for blood cancer patients undergoing CAR-T cell therapy. Findings may advance future clinical practices and promote patient-centered care.